These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32019703)

  • 1. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Baker MA; Jankosky C; Yih WK; Gruber S; Li L; Cocoros NM; Lipowicz H; Coronel-Moreno C; DeLuccia S; Lin ND; McMahill-Walraven CN; Menschik D; Selvan MS; Selvam N; Chen Tilney R; Zichittella L; Lee GM; Kawai AT
    Vaccine; 2020 Feb; 38(9):2166-2171. PubMed ID: 32019703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine.
    Kawai AT; Martin D; Kulldorff M; Li L; Cole DV; McMahill-Walraven CN; Selvam N; Selvan MS; Lee GM
    Pediatrics; 2015 Oct; 136(4):e848-55. PubMed ID: 26371192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.
    Stockwell MS; Broder K; LaRussa P; Lewis P; Fernandez N; Sharma D; Barrett A; Sosa J; Vellozzi C
    JAMA Pediatr; 2014 Mar; 168(3):211-9. PubMed ID: 24395025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months.
    Duffy J; Weintraub E; Hambidge SJ; Jackson LA; Kharbanda EO; Klein NP; Lee GM; Marcy SM; Nakasato CC; Naleway A; Omer SB; Vellozzi C; DeStefano F;
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27273711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.
    Walter EB; Klein NP; Wodi AP; Rountree W; Todd CA; Wiesner A; Duffy J; Marquez PL; Broder KR
    Pediatrics; 2020 Mar; 145(3):. PubMed ID: 32029684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data.
    Kim JH; Yoon D; Lee H; Choe YJ; Shin JY
    Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38302750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System.
    Yih WK; Kulldorff M; Sandhu SK; Zichittella L; Maro JC; Cole DV; Jin R; Kawai AT; Baker MA; Liu C; McMahill-Walraven CN; Selvan MS; Platt R; Nguyen MD; Lee GM
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):481-92. PubMed ID: 26572776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.
    Schwarz TF; Flamaing J; Rümke HC; Penzes J; Juergens C; Wenz A; Jayawardene D; Giardina P; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2011 Jul; 29(32):5195-202. PubMed ID: 21619909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
    Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic antipyretics for prevention of febrile seizures following vaccination.
    Monfries N; Goldman RD
    Can Fam Physician; 2017 Feb; 63(2):128-130. PubMed ID: 28209678
    [No Abstract]   [Full Text] [Related]  

  • 20. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.